Serum Levels of Adrenomedullin in Women with PCOS before and after Rosuvastatin Treatment

Polycystic ovary syndrome is represent one of the prevalent endocrine disorders in women of reproductive age. A part from the important squeal of polycystic ovarian syndrome such as menstrual disturbance, infertility, and excessive hair growth, women with polycystic ovarian syndrome also presented with wide range of secondary consequences including abnormal lipidprofile, hypertension, insulin resistance, hyperandrogenaemia and eventually amplified risk of cardiovascular injury.^(1–3)Adrenomedullin is a vasodilator peptide with 52 amino acids.⁽⁴⁾

This is follow-up study concerning women with polycystic ovarian syndrome, which constitutes a total of 45 women affected with polycystic ovarian syndrome, this study was conducted in Kirkuk City. The serum levels of adrenomedullin was compared before treatment with rosuvastatin with its levels after 3 months treatment with rosuvastatinin a dose of 10 mg/day. The body mass index was calculated for each women included in this study as well as 4 milliliters of venous blood samples were obtained by using a disposable syringe and the samples were kept in plain tubes before and after treatment with rosuvastatin therapy, serum was separated. Serum adrenomedullin was tested by an enzyme linked immunosorbent assay method.

This study showed that the majority of women with polycystic syndrome enrolled in this study were within the age group of 21 to 35 years, this study also reveals that the mean of body mass indexwas 26.01 ± 1.49 Kg/m²forwomen with polycystic ovariansyndrome before treatment and decreased significantly (22.42 ± 1.153 Kg/m²) at a P< 0.01 after treatment with rosuvastatin. The current study found that the serum level of adrenomedullin was elevated significantly (P<0.01) in women with polycystic ovarian syndrome after treatment (397.6 ± 65.1 ng/dl) compared with that before treatment (122.0 ± 12.3 ng/ml). There was a positive correlation between BMI before and after treatment (r = 0.68), also there was a positive correlation between the serum levels adrenomedullin in women with polycystic ovarian syndrome before and after treatment with rosuvastatin (r = 0.36).

It is concluded from this study that the serum levels of adrenomedullin was significantly increased after 3 months of treatment with rosuvastatinin a dose of 10 mg/day in women with polycystic ovarian syndrome.